(Q37866629)

24 August 2017

1 reference

title

Treatment of refractory and recurrent Clostridium difficile infection (English)

1 reference

24 August 2017

Clostridium difficile

0 references

author

Christina M. Surawicz

series ordinal

1

object named as

Christina M Surawicz

1 reference

24 August 2017

Jacob Alexander

2

1 reference

PubMed ID

21502971

24 August 2017

language of work or name

English

0 references

publication date

19 April 2011

1 reference

Nature Reviews Gastroenterology & Hepatology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

6

1 reference

24 August 2017

330-339

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2011.59

24 August 2017

0 references

cites work

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Antimicrobial susceptibilities of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Metronidazole resistance in Clostridium difficile is heterogeneous

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Oral vancomycin for antibiotic-associated pseudomembranous colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Treatment of Clostridium difficile-associated disease with teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

C. difficile colitis--predictors of fatal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Outcomes of emergency colectomy for fulminant Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Surgical aspects of fulminant Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Impact of Clostridium difficile on inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Incidence of Clostridium difficile infection in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Update on the changing epidemiology of Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Clinical predictors and risk factors for relapsing Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Treatment of recurrent Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Safety of probiotics: translocation and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Success of self-administered home fecal transplantation for chronic Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Fecal bacteriotherapy for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Treatment with monoclonal antibodies against Clostridium difficile toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Management of Clostridium difficile infection: thinking inside and outside the box.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Therapeutic transplantation of the distal gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Antibiotic susceptibility of Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

The outcome of surgery in fulminant Clostridium difficile colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Impact of Clostridium difficile on inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Clostridium difficile and inflammatory bowel disease: more questions than answers?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Recurrent Clostridium difficile disease: epidemiology and clinical characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Possible role of cross-transmission between neonates and mothers with recurrent Clostridium difficile infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

The effect of probiotics on Clostridium difficile diarrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Probiotics for recurrent Clostridium difficile disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.59

Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis

31 March 2020

1 reference

12 December 2020

Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection

1 reference

12 December 2020

Failure of tigecycline to treat severe Clostridium difficile infection

1 reference

12 December 2020

Clostridium difficile colitis: factors influencing treatment failure and relapse--a prospective evaluation.

1 reference

12 December 2020

Resolution of recurrent Clostridium difficile-associated diarrhea using staggered antibiotic withdrawal and kefir.

1 reference

12 December 2020

Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis

1 reference

12 December 2020

Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea

1 reference

12 December 2020

Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?

1 reference

12 December 2020

Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2011.59

1 reference

24 August 2017

1 reference

PubMed ID

21502971